Poster Center News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The gentleman from wisconsin. Mr. Ryan i yield two minutes to the gentleman from pennsylvania, mr. Rothfus. Mr. Rothfus i thank chairman ryan for the hard work he has been doing over the last several years as we look to get a handle on the spending problem we have here in washington, d. C. Mr. Chairman, our debt is out of control. In the past 10 years it has doubled from 7. 1 trillion to 17. 6 trillion today. We paid 416 billion in interest just last year. Imagine where that money could have been better spent. Failure to address the debt and deficits reduces opportunity and prosperity for futu...

Spending programs. This is not theoretical, mr. Speaker. The state of illinois has tried that and it is a mess and its a mess that becomes worse the longer the state waits, the worse the options are. And so what the chairman is saying, lets not get to that point. Weve got options. Weve got time. Weve got choices. Weve got remedies, but we need to act now. So i urge favorable consideration of this budget and i yield back the balance of my time. The chair the gentlemans time has expired. The gentleman from maryland is recognized. Mr. Van hollen thank you very much, mr. Chairman. I think for the ...

We are working very, very hard with other countries to work on the overall security issue. I was just in algeria and more ok wroe for the Security Dialogue in the last few days of last week, and we discussed specifically the training of personnel for a Rapid Response force in libya and the greater capacity going forward. I think everybody is concerned about libya in the current status. Thank you. Mr. Secretary, were almost at the end here. I know that senator corker has a few comments to make, and then ill close out, and well get you back to the challenges that we have all collectively face. M...

Galderma the pureplay dermatology category leader will be showcasing its latest clinical and educational efforts at the American Academy of Dermatology AAD Annual Meeting from March 812 2024 highlighting its broad innovative and leading dermatology portfolio.

/PRNewswire/ -- Kyowa Kirin Co., Ltd. (TSE: 4151) today announces that data from the Phase 2b study of rocatinlimab (KHK4083/AMG 451), an investigational...